Liver involvement is often observed in several hematological disorders, resulting in abnormal liver function tests, abnormalities in liver imaging studies, or clinical symptoms presenting with hepatic manifestations. In hemolytic anemia, jaundice and hepatosplenomegaly are often seen mimicking liver diseases. In hematologic malignancies, malignant cells often infiltrate the liver and may demonstrate abnormal liver function test results accompanied by hepatosplenomegaly or formation of multiple nodules in the liver and/or spleen. These cases may further evolve into fulminant hepatic failure. 1. Introduction Hepatologists or general physicians sometimes encounter hepatic manifestations of various hematologic disorders in daily practice, including various abnormalities in liver function tests or imaging studies of the liver. Some hematologic disorders also mimic liver diseases. While review articles regarding hematologic disorders and liver diseases have been published previously [1–3], we also review more recent topics in this paper. 2. Red Blood Cell (RBC) Disorders 2.1. Hemolytic Anemia (HA) 2.1.1. Classification according to the RBC Destruction Site When the RBC membrane is severely damaged, immediate lysis occurs within the circulation (intravascular hemolysis). In cases of less severe damage, the cells may be destroyed within the monocyte-macrophage system in the spleen, liver, bone marrow, and lymph nodes (extravascular hemolysis) [4–6]. 2.1.2. Clinical Presentation Patients with HA typically present with the following findings: rapid onset of anemia, jaundice, history of pigmented (bilirubin) gallstones, and splenomegaly. Mild hepatomegaly can also occur [4]. 2.1.3. Liver Function Tests in HA In hemolysis, serum lactate dehydrogenase (LDH) levels (specifically the LDH1 and LDH2 isoforms) increase because of lysed erythrocytes [4]. Serum aspartate transaminase (AST) levels are also mildly elevated in hemolysis, with the LDH/AST ratio mostly over 30 [7]. Total bilirubin levels can uncommonly exceed 5？mg/dL if hepatic function is normal, except in the case of acute hemolysis caused by sickle cell crisis. Liver dysfunction can also be caused by blood transfusion for anemia in sickle cell disease (SCD) and thalassemia [1, 3]. 2.1.4. Hemolysis in Liver Disease Hemolysis can be caused by either abnormalities in the erythrocyte membranes (intrinsic) or environmental (extrinsic) factors. Most intrinsic causes are hereditary, except for paroxysmal nocturnal hemoglobinuria (PNH) or rare conditions of acquired alpha thalassemia [4]. Extrinsic HA is caused by
References
[1]
N. Gitlin, The Liver and Systemic Disease, Churchill Livingstone, New York, NY, USA, 1997.
[2]
Y. Shimizu, “Liver in systemic disease,” World Journal of Gastroenterology, vol. 14, no. 26, pp. 4111–4119, 2008.
[3]
M. M. Singh and P. J. Pockros, “Hematologic and oncologic diseases and the liver,” Clinics in Liver Disease, vol. 15, no. 1, pp. 69–87, 2011.
[4]
Up-to-Date, “Approach to the diagnosis of hemolytic anemia in the adult,” 2012.
[5]
M. Cazzola and Y. Beguin, “New tools for clinical evaluation of erythron function in man,” British Journal of Haematology, vol. 80, no. 3, pp. 278–284, 1992.
[6]
D. Bossi and B. Giardina, “Red cell physiology,” Molecular Aspects of Medicine, vol. 17, no. 2, pp. 117–128, 1996.
[7]
“The clinical reference guides for the idiopathic hematopoietic disorders,” supported by the Ministry of Health, Labour and Welfare of Japan.
[8]
Up-to-Date, “Extrinsic nonimmune hemolytic anemia due to systemic disease,” 2012.
[9]
H. S. Jacob and T. Amsden, “Acute hemolytic anemia with rigid red cells in hypophosphatemia,” The New England Journal of Medicine, vol. 285, no. 26, pp. 1446–1450, 1971.
[10]
S. Shilo, D. Werner, and C. Hershko, “Acute hemolytic anemia caused by severe hypophosphatemia in diabetic ketoacidosis,” Acta Haematologica, vol. 73, no. 1, pp. 55–57, 1985.
[11]
L. Zieve, “Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis,” Annals of internal medicine, vol. 48, no. 3, pp. 471–496, 1958.
[12]
W. D. Melrose, P. A. Bell, D. M. L. Jupe, and M. J. Baikie, “Alcohol-associated haemolysis in Zieve's syndrome: a clinical and laboratory study of five cases,” Clinical and Laboratory Haematology, vol. 12, no. 2, pp. 159–167, 1990.
[13]
J. Piccini, S. Haldar, and B. Jefferson, “Cases from the Osler medical service at Johns Hopkins university,” American Journal of Medicine, vol. 115, no. 9, pp. 729–731, 2003.
[14]
S. Zeerleder, “Autoimmune haemolytic anaemia—a practical guide to cope with a diagnosticand therapeutic challenge,” Netherlands Journal of Medicine, vol. 69, no. 4, pp. 177–184, 2011.
[15]
C. P. Engelfriet, M. B. Van't Veer, N. Maas, W. H. Ouwehand, D. Beckers, and A. E. G. Von dem Borne Kr. A.E.G., “Autoimmune haemolytic anaemias,” Bailliere's Clinical Immunology and Allergy, vol. 1, no. 2, pp. 251–267, 1987.
[16]
R. S. Shirey, T. S. Kickler, W. Bell, B. Little, B. Smith, and P. M. Ness, “Fatal immune hemolytic anemia and hepatic failure associated with a warm-reacting IgM autoantibody,” Vox Sanguinis, vol. 52, no. 3, pp. 219–222, 1987.
[17]
G. Socié, J. Y. Mary, A. De Gramont et al., “Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors,” The Lancet, vol. 348, no. 9027, pp. 573–577, 1996.
[18]
R. P. De Latour, J. Y. Mary, C. Salanoubat et al., “Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories,” Blood, vol. 112, no. 8, pp. 3099–3106, 2008.
[19]
W. F. Rosse, “Paroxysmal nocturnal hemoglobinuria as a molecular disease,” Medicine, vol. 76, no. 2, pp. 63–93, 1997.
[20]
R. C. Hartmann and D. E. Jenkins, “The “sugar-water” test for paroxysmal nocturnal hemoglobinuria,” The New England Journal of Medicine, vol. 275, no. 3, pp. 155–157, 1966.
[21]
T. H. Ham and J. H. Dingle, “Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement,” The Journal of Clinical Investigation, vol. 18, no. 6, pp. 657–672, 1939.
[22]
W. F. Rosse, “Dr. Ham's test revisited,” Blood, vol. 78, no. 3, pp. 547–550, 1991.
[23]
Up-to-Date, “Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria,” 2012.
[24]
A. Shah, “Acquired hemolytic anemia,” Indian Journal of Medical Sciences, vol. 58, no. 12, pp. 533–536, 2004.
[25]
Up-to-Date, “Overview of the clinical manifestations of sickle cell disease,” 2012.
[26]
S. Banerjee, C. Owen, and S. Chopra, “Sickle cell hepatopathy,” Hepatology, vol. 33, no. 5, pp. 1021–1028, 2001.
[27]
P. A. Berry, T. J. S. Cross, S. L. Thein et al., “Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment,” Clinical Gastroenterology and Hepatology, vol. 5, no. 12, pp. 1469–1476, 2007.
[28]
E. C. Ebert, M. Nagar, and K. D. Hagspiel, “Gastrointestinal and hepatic complications of sickle cell disease,” Clinical Gastroenterology and Hepatology, vol. 8, no. 6, pp. 483–489, 2010.
[29]
C. S. Johnson, M. Omata, and M. J. Tong, “Liver involvement in sickle cell disease,” Medicine, vol. 64, no. 5, pp. 349–356, 1985.
[30]
T. W. Sheehy, “Sickle cell hepatopathy,” Southern Medical Journal, vol. 70, no. 5, pp. 533–538, 1977.
[31]
J. I. Brody, W. N. Ryan, and M. A. Haidar, “Serum alkaline phosphatase isoenzymes in sickle cell anemia,” Journal of the American Medical Association, vol. 232, no. 7, pp. 738–741, 1975.
[32]
K. R. DeVault, L. S. Friedman, S. Westerberg, P. Martin, B. Hosein, and S. K. Ballas, “Hepatitis C in sickle cell anemia,” Journal of Clinical Gastroenterology, vol. 18, no. 3, pp. 206–209, 1994.
[33]
M. B. Leonard, B. S. Zemel, D. A. Kawchak, K. Ohene-Frempong, and V. A. Stallings, “Plasma zinc status, growth, and maturation in children with sickle cell disease,” Journal of Pediatrics, vol. 132, no. 3, pp. 467–471, 1998.
[34]
A. S. Prasad, P. Rabbani, and J. A. Warth, “Effect of zinc on hyperammonemia in sickle cell anemia subjects,” American Journal of Hematology, vol. 7, no. 4, pp. 323–327, 1979.
[35]
N. R. Ghugre and J. C. Wood, “Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model,” Magnetic Resonance in Medicine, vol. 65, no. 3, pp. 837–847, 2011.
[36]
J. S. Hankins, M. P. Smeltzer, M. B. McCarville et al., “Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload,” European Journal of Haematology, vol. 85, no. 1, pp. 51–57, 2010.
[37]
E. S. Siegelman, E. Outwater, C. A. Hanau et al., “Abdominal iron distribution in sickle cell disease: MR findings in transfusion and nontransfusion dependent patients,” Journal of Computer Assisted Tomography, vol. 18, no. 1, pp. 63–67, 1994.
[38]
T. Siegal, U. Seligsohn, E. Aghai, and M. Modan, “Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases,” Thrombosis and Haemostasis, vol. 39, no. 1, pp. 122–134, 1978.
[39]
S. F. Stein and L. A. Harker, “Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis,” Journal of Laboratory and Clinical Medicine, vol. 99, no. 2, pp. 217–230, 1982.
[40]
R. Cervera, J. C. Piette, J. Font et al., “Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients,” Arthritis and Rheumatism, vol. 46, no. 4, pp. 1019–1027, 2002.
[41]
R. A. Asherson, M. A. Khamashta, J. Ordi-Ros et al., “The 'primary' antiphospholipid syndrome: major clinical and serological features,” Medicine, vol. 68, no. 6, pp. 366–374, 1989.
[42]
E. Gromnica-Ihle and W. Schossler, “Antiphospholipid syndrome,” International Archives of Allergy and Immunology, vol. 123, p. 67, 2000.
[43]
I. Uthman and M. Khamashta, “The abdominal manifestations of the antiphospholipid syndrome,” Rheumatology, vol. 46, no. 11, pp. 1641–1647, 2007.
[44]
J. H. Stone, “HELLP syndrome: hemolysis, elevated liver enzymes, and low platelets,” Journal of the American Medical Association, vol. 280, no. 6, pp. 559–562, 1998.
[45]
B. M. Sibai, M. K. Ramadan, I. Usta, M. Salama, B. M. Mercer, and S. A. Friedman, “Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome),” American Journal of Obstetrics and Gynecology, vol. 169, no. 4, pp. 1000–1006, 1993.
[46]
V. A. Catanzarite, S. M. Steinberg, C. A. Mosley, C. F. Landers, L. M. Cousins, and J. M. Schneider, “Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels: high risk for maternal death,” American Journal of Perinatology, vol. 12, no. 5, pp. 310–313, 1995.
[47]
M. Ramos-Casals, J. H. Stone, M. C. Cid, and X. Bosch, “The cryoglobulinaemias,” The Lancet, vol. 379, no. 9813, pp. 348–360, 2012.
[48]
J. C. Brouet, J. P. Clauvel, and F. Danon, “Biologic and clinical significance of cryoglobulins. A report of 86 cases,” American Journal of Medicine, vol. 57, no. 5, pp. 775–788, 1974.
[49]
A. D. Rossa, G. Trevisani, and S. Bombardieri, “Cryoglobulins and cryoglobulinemia: diagnostic and therapeutic considerations,” Clinical Reviews in Allergy and Immunology, vol. 16, no. 3, pp. 249–264, 1998.
[50]
F. Invernizzi, P. Pioltelli, and R. Cattaneo, “A long-term follow-up study in essential cryoglobulinemia,” Acta Haematologica, vol. 61, no. 2, pp. 93–99, 1979.
[51]
L. La Civita, A. L. Zignego, M. Monti, G. Longombardo, G. Pasero, and C. Ferri, “Mixed cryoglobulinemia as a possible preneoplastic disorder,” Arthritis and Rheumatism, vol. 38, no. 12, pp. 1859–1860, 1995.
[52]
D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J. C. Piette, and P. Cacoub, “Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2101–2108, 2006.
[53]
P. Pileri, Y. Uematsu, S. Campagnoli et al., “Binding of hepatitis C virus to CD81,” Science, vol. 282, no. 5390, pp. 938–941, 1998.
[54]
V. Agnello, R. T. Chung, and L. M. Kaplan, “A role for hepatitis C virus infection in type II cryoglobulinemia,” The New England Journal of Medicine, vol. 327, no. 21, pp. 1490–1495, 1992.
[55]
V. Agnello, “The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection,” Springer Seminars in Immunopathology, vol. 19, no. 1, pp. 111–129, 1997.
[56]
E. D. Charles, R. M. Green, S. Marukian et al., “Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia,” Blood, vol. 111, no. 3, pp. 1344–1356, 2008.
[57]
G. B. Knight, L. Gao, L. Gragnani et al., “Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies,” Arthritis and Rheumatism, vol. 62, no. 7, pp. 2152–2159, 2010.
[58]
E. D. Charles, C. Brunetti, S. Marukian et al., “Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset,” Blood, vol. 117, no. 20, pp. 5425–5437, 2011.
[59]
P. Schott, F. Polzien, A. Müller-Issberner, G. Ramadori, and H. Hartmann, “In vitro reactivity of cryoglobulin IgM and IgG in hepatitis C virus- associated mixed cryoglobulinemia,” Journal of Hepatology, vol. 28, no. 1, pp. 17–26, 1998.
[60]
O. Boyer, D. Saadoun, J. Abriol et al., “CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis,” Blood, vol. 103, no. 9, pp. 3428–3430, 2004.
[61]
G. Montagnino, “Reappraisal of the clinical expression of mixed cryoglobulinemia,” Springer Seminars in Immunopathology, vol. 10, no. 1, pp. 1–19, 1988.
[62]
S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008.
[63]
S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H. M. Kantarjian, “The biology of chronic myeloid leukemia,” The New England Journal of Medicine, vol. 341, no. 3, pp. 164–172, 1999.
[64]
D. G. Savage, R. M. Szydlo, and J. M. Goldman, “Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period,” British Journal of Haematology, vol. 96, no. 1, pp. 111–116, 1997.
[65]
F. Cervantes and C. Rozman, “A multivariate analysis of prognostic factors in chronic myeloid leukemia,” Blood, vol. 60, no. 6, pp. 1298–1304, 1982.
[66]
S. M. Ondreyco, C. R. Kjeldsberg, and R. M. Fineman, “Monoblastic transformation in chronic myelogenous leukemia: presentation with massive hepatic involvement,” Cancer, vol. 48, no. 4, pp. 957–963, 1981.
[67]
N. I. Berlin, “Diagnosis and classification of the polycythemias,” Seminars in Hematology, vol. 12, no. 4, pp. 339–351, 1975.
[68]
T. C. Pearson and M. Messinezy, “The diagnostic criteria of polycythaemia rubra vera,” Leukemia and Lymphoma, vol. 22, supplement 1, pp. 87–93, 1996.
[69]
J. J. Michiels and E. Juvonen, “Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group,” Seminars in Thrombosis and Hemostasis, vol. 23, no. 4, pp. 339–347, 1997.
[70]
G. Torgano, C. Mandelli, P. Massaro et al., “Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori,” British Journal of Haematology, vol. 117, no. 1, pp. 198–202, 2002.
[71]
D. Valla, N. Casadevall, and C. Lacombe, “Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome,” Annals of Internal Medicine, vol. 103, no. 3, pp. 329–334, 1985.
[72]
G. Visani, C. Finelli, U. Castelli et al., “Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients,” British Journal of Haematology, vol. 75, no. 1, pp. 4–9, 1990.
[73]
M. N. Silverstein, Agnogenic Myeloid Metaplasia, Publishing Sciences Group, Acton, Mass, USA, 1975.
[74]
A. Varki, R. Lottenberg, R. Griffith, and E. Reinhard, “The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival,” Medicine, vol. 62, no. 6, pp. 353–371, 1983.
[75]
F. Lioté, P. Yeni, F. Teillet-Thiebaud et al., “Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature,” American Journal of Medicine, vol. 90, no. 1, pp. 111–117, 1991.
[76]
A. Lopéz-Guillermo, F. Cervantes, M. Bruguera, A. Pereira, E. Feliu, and C. Rozman, “Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients,” Acta Haematologica, vol. 85, no. 4, pp. 184–188, 1991.
[77]
J. Thiele, H. M. Kvasnicka, C. Werden, R. Zankovich, V. Diehl, and R. Fischer, “Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact,” Leukemia and Lymphoma, vol. 22, no. 3-4, pp. 303–317, 1996.
[78]
P. A. Beer, P. J. Campbell, and A. R. Green, “Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase,” Haematologica, vol. 95, no. 11, pp. 1960–1963, 2010.
[79]
M. Primignani, I. Martinelli, P. Bucciarelli et al., “Risk factors for thrombophilia in extrahepatic portal vein obstruction,” Hepatology, vol. 41, no. 3, pp. 603–608, 2005.
[80]
D. Valla, N. Casadevall, M. G. Huisse et al., “Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders,” Gastroenterology, vol. 94, no. 4, pp. 1063–1069, 1988.
[81]
J. Hoekstra, E. L. Bresser, J. H. Smalberg, M. C. Spaander, F. W. Leebeek, and H. L. Janssen, “Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms,” Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2208–2214.
[82]
S. P'ng, B. Carnley, R. Baker, N. Kontorinis, and W. Cheng, “Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation,” Clinical Gastroenterology and Hepatology, vol. 6, no. 4, pp. 472–475, 2008.
[83]
X. Qi, Z. Yang, M. Bai, X. Shi, G. Han, and D. Fan, “Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 10, pp. 1087–1103, 2011.
[84]
S. D. Murad, A. Plessier, M. Hernandez-Guerra et al., “Etiology, management, and outcome of the Budd-Chiari syndrome,” Annals of Internal Medicine, vol. 151, no. 3, pp. 167–175, 2009.
[85]
M. Primignani, G. Barosi, G. Bergamaschi et al., “Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis,” Hepatology, vol. 44, no. 6, pp. 1528–1534, 2006.
[86]
R. K. Patel, N. C. Lea, M. A. Heneghan et al., “Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome,” Gastroenterology, vol. 130, no. 7, pp. 2031–2038, 2006.
[87]
Up-to-Date, “Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma,” 2012.
[88]
A. Ross and L. S. Friedman, “The liver in systemic disease,” in Comprehensive Clinical Hepatology, B. R. Bacon, J. G. O’Grady JG, A. M. Di Bisceglie, and J. R. Lake, Eds., p. 537, Mosby Elsevier, Philadelphia, Pa, USA, 2nd edition, 2006.
[89]
S. G. Hubscher, M. A. Lumley, and E. Elias, “Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma,” Hepatology, vol. 17, no. 1, pp. 70–77, 1993.
[90]
S. Guliter, O. Erdem, M. Isik, K. Yamac, and O. Uluoglu, “Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) in Hodgkin's disease: report of a case,” Tumori, vol. 90, no. 5, pp. 517–520, 2004.
[91]
I. Leeuwenburgh, E. P. J. Lugtenburg, H. R. Van Buuren, P. E. Zondervan, and R. A. De Man, “Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 2, pp. 145–147, 2008.
[92]
D. Rowbotham, J. Wendon, and R. Williams, “Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases,” Gut, vol. 42, no. 4, pp. 576–580, 1998.
[93]
T. M. Shehab, M. S. Kaminski, and A. S. F. Lok, “Acute liver failure due to hepatic involvement by hematologic malignancy,” Digestive Diseases and Sciences, vol. 42, no. 7, pp. 1400–1405, 1997.
[94]
E. S. Jaffe, “Malignant lymphomas: pathology of hepatic involvement,” Seminars in Liver Disease, vol. 7, no. 3, pp. 257–268, 1987.
[95]
J. . Salo', B. Nomdedeu, M. Bruguera et al., “Acute liver failure due to non-Hodgkin’s lymphoma,” The American Journal of Gastroenterology, vol. 88, no. 5, pp. 774–776, 1993.
[96]
E. Vardareli, E. Dundar, V. Aslan, and Z. Gulbas, “Acute liver failure due to Hodgkin's lymphoma,” Medical Principles and Practice, vol. 13, no. 6, pp. 372–374, 2004.
[97]
S. P. Dourakis, E. Tzemanakis, M. Deutsch, G. Kafiri, and S. J. Hadziyannis, “Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease,” European Journal of Gastroenterology and Hepatology, vol. 11, no. 9, pp. 1055–1058, 1999.
[98]
D. Rowbotham, J. Wendon, and R. Williams, “Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases,” Gut, vol. 42, no. 4, pp. 576–580, 1998.
[99]
J. F. Emile, D. Azoulay, J. M. Gornet et al., “Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses,” Annals of Oncology, vol. 12, no. 7, pp. 1005–1010, 2001.
[100]
G. A. Morali, E. Rozenmann, J. Ashkenazi, G. Munter, and D. Z. Braverman, “Acute liver failure as the sole manifestation of relapsing non-Hodgkin's lymphoma,” European Journal of Gastroenterology and Hepatology, vol. 13, no. 10, pp. 1241–1243, 2001.
[101]
M. Yeshurun, F. Isnard, L. Garderet et al., “Acute liver failure as initial manifestation of low-grade non-Hodgkin's lymphoma transformation into large-cell lymphoma,” Leukemia and Lymphoma, vol. 42, no. 3, pp. 555–559, 2001.
[102]
G. M. Woolf, L. M. Petrovic, S. E. Rojter et al., “Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation,” Digestive Diseases and Sciences, vol. 39, no. 6, pp. 1351–1358, 1994.
[103]
M. Bruguera and R. Miquel, “The effect of hematological and lymphatic diseases on the liver,” in Textbook of Hepatology, J. Rodés, J. P. Benhaumou, A. T. Blei, J. Reichen, and M. Rizzetto, Eds., p. 1662, Blackwell, Oxford, UK, 3rd edition, 2007.
[104]
D. R. Goffinet, R. A. Castellino, and H. Kim, “Staging laparotomies in unselected previously untreated patients with non Hodgkin's lymphomas,” Cancer, vol. 32, no. 3, pp. 672–681, 1973.
[105]
R. Risdall, T. Hoppe, and R. Warnke, “Non-Hodgkin's lymphoma. A study of the evolution of the disease based upon 92 autopsied cases,” Cancer, vol. 44, no. 2, pp. 529–542, 1979.
[106]
G. Civardi, D. Vallisa, R. Bertè, A. Lazzaro, C. F. Moroni, and L. Cavanna, “Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection,” European Journal of Cancer, vol. 38, no. 18, pp. 2382–2387, 2002.
[107]
A. Masood, S. Kairouz, K. H. Hudhud, A. Z. Hegazi, A. Banu, and N. C. Gupta, “Primary non-Hodgkin lymphoma of liver,” Current Oncology, vol. 16, no. 4, pp. 74–77, 2009.
[108]
F. S. Haider, R. Smith, and S. Khan, “Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report,” Journal of Medical Case Reports, vol. 2, article no. 279, 2008.
[109]
D. Baumhoer, A. Tzankov, S. Dirnhofer, L. Tornillo, and L. M. Terracciano, “Patterns of liver infiltration in lymphoproliferative disease,” Histopathology, vol. 53, no. 1, pp. 81–90, 2008.
[110]
A. M. Cameron, J. Truty, J. Truell et al., “Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy,” Transplantation, vol. 80, no. 7, pp. 993–996, 2005.
[111]
K. Kikuma, J. Watanabe, Y. Oshiro et al., “Etiological factors in primary hepatic B-cell lymphoma,” Virchows Archiv, vol. 460, no. 4, pp. 379–387, 2012.
[112]
T. Izumi, R. Sasaki, Y. Miura, and H. Okamoto, “Primary hepatosplenic lymphoma: association with hepatitis C virus infection,” Blood, vol. 87, no. 12, pp. 5380–5381, 1996.
[113]
M. Yoshikawa, Y. Yamane, S. Yoneda et al., “Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus,” Journal of Gastroenterology, vol. 33, no. 6, pp. 880–885, 1998.
[114]
A. J. M. Ferreri, E. Campo, J. F. Seymour et al., “Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant',” British Journal of Haematology, vol. 127, no. 2, pp. 173–183, 2004.
[115]
K. Shimada, K. Matsue, K. Yamamoto et al., “Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL Study Group in Japan,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3189–3195, 2008.
[116]
J. E. Chapin, L. E. Davis, M. Kornfeld, and R. N. Mandler, “Neurologic manifestations of intravascular lymphomatosis,” Acta Neurologica Scandinavica, vol. 91, no. 6, pp. 494–499, 1995.
[117]
M. E. Detsky, L. Chiu, M. R. Shandling, M. E. Sproule, and M. R. Ursell, “Heading down the wrong path,” The New England Journal of Medicine, vol. 355, no. 1, pp. 67–74, 2006.
[118]
T. Murase, M. Yamaguchi, R. Suzuki et al., “Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5,” Blood, vol. 109, no. 2, pp. 478–485, 2007.
[119]
T. Murase, S. Nakamura, K. Kawauchi et al., “An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome,” British Journal of Haematology, vol. 111, no. 3, pp. 826–834, 2000.
[120]
K. Kojima, K. Kaneda, M. Yasukawa et al., “Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome,” British Journal of Haematology, vol. 119, no. 3, pp. 616–621, 2002.
[121]
H. Narimatsu, Y. Morishita, S. Saito et al., “Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases,” Leukemia and Lymphoma, vol. 45, no. 8, pp. 1611–1616, 2004.
[122]
K. Shimada, T. Murase, K. Matsue et al., “Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients,” Cancer Science, vol. 101, no. 6, pp. 1480–1486, 2010.
[123]
J. R？glin and A. B？er, “Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin,” British Journal of Dermatology, vol. 157, no. 1, pp. 16–25, 2007.
[124]
M. Ponzoni, A. J. M. Ferreri, E. Campo et al., “Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3168–3173, 2007.
[125]
S. Ganguly, “Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab,” American Journal of Clinical Oncology, vol. 30, no. 2, pp. 211–212, 2007.
[126]
M. Martusewicz-Boros, E. Wiatr, E. Radzikowska, K. Roszkowski-Sliz, and R. Langfort, “Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2137–2139, 2007.
[127]
S. Yamada, R. Nishii, S. Oka et al., “FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma,” Archives of Neurology, vol. 67, no. 3, pp. 366–367, 2010.
[128]
J. R. Rosh, T. Gross, P. Mamula, A. Griffiths, and J. Hyams, “Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?” Inflammatory Bowel Diseases, vol. 13, no. 8, pp. 1024–1030, 2007.
[129]
F. Beigel, M. Jürgens, C. Tillack et al., “Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease,” Nature Reviews Gastroenterology and Hepatology, vol. 6, pp. 433–436, 2009.
[130]
C. Créput, L. Galicier, S. Buyse, and E. Azoulay, “Understanding organ dysfunction in hemophagocytic lymphohistiocytosis,” Intensive Care Medicine, vol. 34, no. 7, pp. 1177–1187, 2008.
[131]
G. E. Janka, “Hemophagocytic syndromes,” Blood Reviews, vol. 21, pp. 245–253, 2007.
[132]
C. De Kerguenec, S. Hillaire, V. Molinié et al., “Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases,” American Journal of Gastroenterology, vol. 96, no. 3, pp. 852–857, 2001.
[133]
L. Arcaini, M. Lazzarino, N. Colombo et al., “Splenic marginal zone lymphoma: a prognostic model for clinical use,” Blood, vol. 107, no. 12, pp. 4643–4649, 2006.
[134]
M. Bruguera and R. Miquel, “The effect of hematological and lymphatic diseases on the liver,” in Textbook of Hepatology, J. Rodés, J. P. Benhaumou, A. T. Blei, J. Reichen, and M. Rizzetto, Eds., p. 1662, Blackwell, Oxford, UK, 3rd edition, 2007.
[135]
D. L. Thiele, “Hepatic manifestations of systemic disease and other disorders of the liver,” in Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, M. Feldman, L. S. Friedman, and M. H. Sleisenger, Eds., p. 1603, Elsevier Science, Philadelphia, Pa, USA, 7th edition, 2002.
[136]
J. B. Litten, M. M. Rodríguez, and V. Maniaci, “Acute lymphoblastic leukemia presenting in fulminant hepatic failure,” Pediatric Blood and Cancer, vol. 47, no. 6, pp. 842–845, 2006.
[137]
J. F. Margolin, C. P. Steuber, and D. G. Poplack, “Acute lymphoblastic leukemia,” in Principles and Practice of Pediatric Oncology, P. A. Pizzo and D. G. Poplack, Eds., p. 489, Lippincott-Raven, Philadelphia, Pa, USA, 4th edition, 2001.
[138]
R. A. Streuli, Y. Kaneko, and D. Variakojis, “Lymphoblastic lymphoma in adults,” Cancer, vol. 47, no. 10, pp. 2510–2516, 1981.
[139]
E. A. Copelan and E. A. McGuire, “The biology and treatment of acute lymphoblastic leukemia in adults,” Blood, vol. 85, no. 5, pp. 1151–1168, 1995.
[140]
A. M. Tsimberidou, S. Wen, S. O'Brien et al., “Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4648–4656, 2007.
[141]
F. Fais, F. Ghiotto, S. Hashimoto et al., “Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors,” Journal of Clinical Investigation, vol. 102, no. 8, pp. 1515–1525, 1998.
[142]
R. N. Damle, F. Ghiotto, A. Valetto et al., “B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes,” Blood, vol. 99, no. 11, pp. 4087–4093, 2002.
[143]
F. K. Stevenson and F. Caligaris-Cappio, “Chronic lymphocytic leukemia: revelations from the B-cell receptor,” Blood, vol. 103, no. 12, pp. 4389–4395, 2004.
[144]
D. Catovsky, “Hairy-cell leukaemia and prolymphocytic leukaemia,” Clinics in Haematology, vol. 6, no. 1, pp. 245–268, 1977.
[145]
J. L. Binet, A. Auquier, G. Dighiero et al., “A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis,” Cancer, vol. 48, no. 1, pp. 198–206, 1981.
[146]
K. R. Rai, A. Sawitsky, and E. P. Cronkite, “Clinical staging of chronic lymphocytic leukemia,” Blood, vol. 46, no. 2, pp. 219–234, 1975.
[147]
J. B. Schwartz and A. M. Shamsuddin, “The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia,” Human Pathology, vol. 12, no. 5, pp. 432–440, 1981.
[148]
J. Y. Wilputte, J. P. Martinet, P. Nguyen, P. Damoiseaux, J. Rahier, and A. Geubel, “Chronic lymphocytic leukemia with portal hypertension and without liver involvement: a case report underlining the roles of increased spleno-portal blood flow and “protective” sinusoidal vasoconstriction,” Acta Gastro-Enterologica Belgica, vol. 66, no. 4, pp. 303–306, 2003.
[149]
H. M. Golomb, D. Catovsky, and D. W. Golde, “Hairy cell leukemia. A clinical review based on 71 cases,” Annals of Internal Medicine, vol. 89, no. 5, pp. 677–683, 1978.
[150]
M. R. Grever, “How I treat hairy cell leukemia,” Blood, vol. 115, no. 1, pp. 21–28, 2010.
[151]
L. T. Yam, A. J. Janckila, C. H. Chan, and C. Y. Li, “Hepatic involvement in hairy cell leukemia,” Cancer, vol. 51, no. 8, pp. 1497–1504, 1983.
[152]
R. A. Kyle, M. A. Gertz, T. E. Witzig et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” Mayo Clinic Proceedings, vol. 78, no. 1, pp. 21–33, 2003.
[153]
R. Perez-Soler, R. Esteban, and E. Allende, “Liver involvement in mutliple myeloma,” American Journal of Hematology, vol. 20, no. 1, pp. 25–29, 1985.
[154]
H. Chang, E. S. Bartlett, B. Patterson, C. I. Chen, and Q. L. Yi, “The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system,” British Journal of Haematology, vol. 129, no. 4, pp. 539–541, 2005.
[155]
Up-to-Date, “An overview of amyloidosis,” 2012.
[156]
F. S. Buck and M. N. Koss, “Hepatic amyloidosis: morphologic differences between systemic AL and AA types,” Human Pathology, vol. 22, no. 9, pp. 904–907, 1991.
[157]
T. Iwata, Y. Hoshii, H. Kawano et al., “Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins,” Human Pathology, vol. 26, no. 10, pp. 1148–1153, 1995.
[158]
R. A. Levine, “Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients,” The American Journal of Medicine, vol. 33, no. 3, pp. 349–357, 1962.
[159]
B. Sarsik, S. Sen, F. S. Kirdok, U. S. Akarca, H. Toz, and F. Yilmaz, “Hepatic amyloidosis: morphologic spectrum of histopathological changes in AA and nonAA amyloidosis,” Pathology—Research and Practice, vol. 208, no. 12, pp. 713–718, 2012.
[160]
Y. D. Wang, C. Y. Zhao, and H. Z. Yin, “Primary hepatic amyloidosis: a mini literature review and five cases report,” Annals of Hepatology, vol. 11, pp. 721–727, 2012.
